A Phase Ⅲ Clinical Trial of HLX22
Phase 3
550
about 3.8 years
18+
29 sites in CA, CO, FL +11
What this study is about
Researchers are testing a treatment called HLX22 when used with trastuzumab and chemotherapy as the first treatment for HER2-positive gastric or gastroesophageal junction cancer. The trial will last about 1379 days, and it involves comparing this new treatment to standard care.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Capecitabine
- 2.Take HLX22
- 3.Take Oxaliplatin
- +2 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
capecitabine, oxaliplatin, pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer), trastuzumab (Monoclonal antibody; targets HER2 protein on cancer cells)
oral (Oral Tablet), injection (Injection), infusion, injection, intravenous
Primary: Overall Survival （OS）, Progression-Free Survival (PFS)per RECIST 1.1 assessed by IRRC(Independent Radiology Review Committee)
Secondary: Adverse events (AE), Objective Response Rate (ORR) assessed by IRRC and investigator per RECIST v1.1, PFS per RECIST 1.1 assessed by investigator